All In Biotech

BLA 761060 · Wyeth Pharms INC

Mylotarg

Gemtuzumab Ozogamicin · Single-Dose · CD33-directed Immunoconjugate

Orphan

Last checked: Nov 20, 2026Latest source record: Jun 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Sep 1, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

105

26 Phase 3, 17 recruiting

FAERS reports

3,665

3,554 serious, 1,135 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with MYLOTARG. ( 5.1 and 6.1 ) WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG. ( 5.1 , 6.1 )

What it is approved for

From the label in effect Dec 19, 2025.

MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: • treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). • treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older ( 1.2 ). 1.1 Newly-Diagnosed CD33-positive Acute Myeloid Leukemia (AML) MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older. 1.2 Relapsed or Refractory CD33-positive AML MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.

Mechanism: Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 antigen. The small molecule, N-acetyl gamma calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of gemtuzumab ozogamicin is due to the binding of the ADC to CD33-expressing tumor cells, followed by internalization of the ADC-CD33 complex, and the intracellular release of N-acetyl gamma calicheamicin dimethyl hydrazide via hydrolytic cleavage of the linker. Activation of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 16, 2020 Supplement 4 · Efficacy · priority review OrphanLabelLetter
  • Sep 1, 2017 Original approval · Type 4 - New Combination OrphanLabelLetterReview
  • Sep 1, 2017 Original approval · Efficacy OrphanLetterReview
1 products under this application
  • MYLOTARG · GEMTUZUMAB OZOGAMICIN 4.5MG · VIAL, SINGLE-DOSE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gemtuzumab Ozogamicin" as an intervention, any sponsor and status, largest first.

All 105 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia698
  • pyrexia326
  • sepsis302
  • venoocclusive liver disease260
  • thrombocytopenia240
  • platelet count decreased236
  • pneumonia197
  • neutropenia194
  • white blood cell count decreased185
  • aspartate aminotransferase increased184
  • off label use174
  • alanine aminotransferase increased163

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004127
2005156
2006311
2007192
2008118
2009135
2010135
2011200
2012101
201364
201452
201583
201677
2017122
2018221
2019177
2020259
2021315
2022242
2023220
2024149
2025129
202677

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Mylotarg (Gemtuzumab Ozogamicin) · HCPCS J9203

2024 spending

$2.4M

Beneficiaries

91

194 claims

Per beneficiary

$26,779

2024 ASP limit $227.98 per unit

View as table
YearSpending
2020$3,602,963
2021$2,808,760
2022$3,169,326
2023$2,267,759
2024$2,436,886

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 162 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.